Hit enter to search or ESC to close

Author: Kerry Rowe

Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson’s Disease and Movement Disorders

– Wearable sensors strongly correlated with clinical scales on motor impairment – – bioMUSE Study Validates Use of Wearable Sensors for Alterity’s Ongoing Phase 2 Clinical Trial – Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster from ...

WEBCAST LINK: 34th Annual Roth Conference

All stakeholders of Alterity Therapeutics, are invited to register to view the Company’s presentation at the 34th Annual Roth Conference. The conference is taking place Monday, 14 March and Tuesday, 15 March 2022 in Dana Point, California, USA. Link to registration: https://wsw.com/webcast/roth43/athe/1810184

Change of Company Name

We wish to announce the Company name change has been processed by the Australian Securities and Investment Commission and the Company has changed its name from “Prana Biotechnology Limited” to “Alterity Therapeutics Limited”.